Layered double hydroxide nanoparticles as an adjuvant for inactivated foot-and-mouth disease vaccine in pigs

被引:0
作者
Peng Wu
Yunfeng Zhang
Xinyue Yin
Yanhua He
Qian Zhang
Chuangfu Chen
机构
[1] Shihezi University,College of Animal Science and Technology
[2] Shihezi University,College of Life Technology
[3] State Key Laboratory of Sheep Genetic Improvement and Healthy Production/ Xinjiang Academy of Agricultural and Reclamation Sciences,undefined
来源
BMC Veterinary Research | / 16卷
关键词
LDHs; FMDV; NPs; Adjuvant; Immune response;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 125 条
[1]  
Cao YM(2014)Adjuvants for foot-and-mouth disease virus vaccines: recent progress Expert Rev Vaccines 13 1377-1385
[2]  
Diaz-San Segundo F(2017)Foot-and-mouth disease vaccines Vet Microbiol 206 102-112
[3]  
Medina GN(2015)Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine Vet World 8 1189-1198
[4]  
Stenfeldt C(2007)Improvement of a commercial foot-and-mouth disease vaccine by supplement of Quil a Vaccine. 25 4795-4800
[5]  
Ibrahim EE(2012)Improved neutralising antibody response against foot-and-mouth-disease virus in mice inoculated with a multi-epitope peptide vaccine using polyinosinic and poly-cytidylic acid as an adjuvant J Virol Methods 185 124-128
[6]  
Gamal WM(2013)Co-administration of flagellin augments immune responses to inactivated foot-and-mouth disease virus (FMDV) antigen Res Vet Sci 95 936-941
[7]  
Hassan AI(2005)Interleukin-2 potentiates foot-and-mouth disease vaccinal immune responses in mice Vaccine. 23 3005-3009
[8]  
Mahdy SE(2008)Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon α in mice and protective efficacy in Guinea pigs and swine J Virol Methods 149 144-152
[9]  
Hegazy AZ(2008)Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18 Vet Immunol Immunop 121 1-7
[10]  
Abdel-Atty MM(2011)Immune responses to the oral administration of recombinant J Virol Methods 171 272-279